3P Biopharmaceuticals and Invizius hope for reducing the cardiovascular complications associated with dialysis

Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease

<!–

Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease.

Invizius, a Scottish biotech company and 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, have initiated a collaboration on an innovative treatment for reducing the cardiovascular complications with dialysis treatments.

Invizius and 3P Biopharmaceuticals began their partnership earlier this year when 3P Biopharmaceuticals was selected to be responsible for cGMP manufacturing in preparation for First-in-Human trials.

Currently, life expectancy of patients on dialysis is just one-third of normal, and half of these patients die from cardiovascular complications. The immune systems of these patients see the dialysis filter as a foreign body, creating inflammation that damages the cardiovascular system over time. Recent research reveals that patients with a higher immune response to dialysis are at higher risk of cardiovascular complications.

Hope for reducing the cardiovascular complications with dialysis

Invizius’s innovative H-Guard® product is a powerful anti-inflammatory that can be used to coat the filter surface to ‘hide’ it and prevent an immune response, potentially reducing cardiovascular damage and improving patients’ quality of life.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “This pioneering project offers an extraordinary hope for improving the lives of dialysis patients affected by treatment-driven complications. Therefore, we are delighted to collaborate with Invizius on such a stimulating project.

Richard Boyd, CEO at Invizius, added: “H-Guard may represent the greatest advance in dialysis medicine in the last 25 years, a period in which there has been no significant innovation for patients, and clinical outcomes have languished and remain among the worst in modern medicine. We are delighted to be working with 3P Biopharmaceuticals to bring this pioneering treatment to the clinic.

The technology also has potential for use with devices such as heart and lung machines, stents and grafts, or in organ transplants and cell therapies. Invizius has won awards including OBN Best Innovative Medtech and was named as one of the Fierce 15 Medtech companies to watch.

With this partnership, 3P Biopharmaceuticals confirms its capability to carry out processes and manufacture molecules developed within diverse therapeutic applications.

Our dedicated team of specialists will be happy to discuss any of your biopharmaceutical needs. Contact us on +34 948 346 480 or email itswithinus@3pbio.com

Related Content

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

3P Biopharmaceuticals appoints Diego Bochoeyer as Director of Strategic Development and Supply Chain

3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain.
Read more

3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology

3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.